Suchen Sie nach Informationen zu Astellas Neue US-Zentrale? Folgen Sie den Links unten, um alle Informationen zu finden, die Sie benötigen, und mehr.
https://www.astellas.com/us/
Learn more about our commitment to patients and available resources. Call us at (800) 888-7704, M-F, 8AM-7PM CT.
https://www.astellas.com/us/about/locations
Astellas Pharma US, Inc. Astellas US Headquarters Northbrook, Illinois 1-800-888-7704. Astellas Pharma Global Development, Inc. Northbrook, Illinois 1-800-888-7704. Astellas Policy and Government Affairs. Washington, D.C 1-202-741-1961. Astellas Research Institute of America LLC. Research San Diego, California 1-847-933-7400. Astellas Venture ...
https://www.astellas.com/us/news/1366
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and …
https://www.astellas.com/us/news/2461
NORTHBROOK, Ill., Jan. 22, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. today announced that its new headquarters for the Americas, located at the northwest corner of I-294 and Willow Road in Northbrook, has been awarded LEED Gold certification by the U.S. Green Building Council (USGBC). LEED, which stands for Leadership in Energy and Environmental …
https://www.astellas.com/en/
Astellas was established in 2005 through merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical CO., Ltd. and has a rich history spanning over 100 years. Annual Report 2021. Annual Report 2021 Integrated with the CSR report.
https://newsroom.astellas.us/2022-06-08-Astellas-Celebrates-the-Opening-of-Its-New-Large-Scale-Gene-Therapy-Manufacturing-Facility-in-North-Carolina
- Astellas' $100 million investment in Lee County facility to support more than 200 new jobs. TOKYO and SANFORD, N.C., June 8, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the opening of a new late-stage clinical and commercial manufacturing facility in Sanford, N.C.
https://www.astellas.com/us/news/6316
Astellas is reviewing potential financial impacts of this matter for the fiscal year ending March 31, 2023. About Pompe Disease. Pompe disease is a rare, severe, autosomal recessive metabolic disease characterized by progressive muscular degeneration. The overall incidence is estimated to be approximately 1 in 40,000 births 1 , although frequency and …
https://newsroom.astellas.us/Astellas-Announces-Recent-Leadership-Promotions-in-Medical-Development,-Primary-Focuses,-Commercial,-Product-Management-and-Human-Resources
Astellas is proud to share recent top leadership promotions and appointments across our divisions for employees based in the US. These leaders are all crucial in driving forward the company’s vision, innovation and commitment to the patients and healthcare providers we serve. Andrew Krivoshik, M.D., Ph.D., was promoted to president of ...
https://newsroom.astellas.us/Promoting-Patient-Access-in-the-States-Video-Discussion-featuring-Astellas-US-President-Mark-Reisenauer
Astellas Pharma US President Mark Reisenauer recently joined PhRMA Senior Vice President of State Advocacy Scott LaGanga for a conversation about a range of topics that are important to patients – from the latest in medical science to the ways that biopharmaceutical companies, policymakers and other stakeholders are working to lower out-of-pocket costs.
https://www.astellas.com/de/
Offen neue Wege beschreiten, um die Zukunft im Gesundheitswesen mitzugestalten – darum geht es auch in unserem Podcast. Hören Sie rein! ... Um die Gesundheit möglichst vieler Menschen zu verbessern, engagiert sich Astellas Pharma Deutschland in verschiedenen nationalen und internationalen Gesundheits-und Präventionsprojekten. Lesen Sie ...
Wir hoffen, dass Sie über die obigen Links alle notwendigen Informationen zu Astellas Neue US-Zentrale gefunden haben.
